Skip to main content

Advertisement

SpringerLink
Log in

Tolerance of Chemoradiation in Advanced Head and Neck Cancers: Comparison Between Inpatients and Outpatients

  • Original Article
  • Published:
Indian Journal of Otolaryngology and Head & Neck Surgery Aims and scope Submit manuscript

Abstract

Concurrent chemoradiation (CCRT) is the mainstay of treatment for majority of locally advanced head and neck carcinomas (LAHNC). Addition of chemotherapy to radiotherapy increases the probability of local control and improved disease-free survival but at the cost of acute and delayed toxicities. A retrospective observational study. To compare the tolerance of CCRT and its toxicity profile amongst two groups, first arm (Arm A) being outdoor patients and the second group (Arm B) was hospitalized patients of LAHNC in an oncology centre of a tertiary care hospital. A total of 100 patients were enrolled, 50 in each arm. Overall, the most common site was oropharynx, followed by larynx and hypopharynx. 38 patients in Arm A received full 6 cycles of weekly chemotherapy with Inj Cisplatin infusion. 39 of the hospitalized patients completed 6 cycles of weekly Cisplatin, 04 patients also received 3 weekly Cisplatin. Average duration of treatment was 49.18 days in arm A and 50.92 days in arm B. Incidence of Grade II onwards dysphagia was 48 and 45 (96 and 90%) in Arm A and Arm B respectively; Chi Square value—0.6 (Yate’s corrected); P value—0.43. Grade III oral mucositis was seen in 14% patients in Arm A and 34% patients in Arm B. 3 patients (6%) in Arm A and 14 patients (28%) in Arm B has Grade II and III hematological toxicities and nephrological toxicities. Aspiration pneumonia was seen in 2 patients (4%) in Arm A and in 4 patients (8%) in Arm B, Chi Square value—0.2 (Yate’s corrected) P value—0.67. The incidence of febrile neutropenia was 3 and 10 in Arms A and B (6 and 20%) respectively. The tolerance of CCRT in hospitalized patients is marginally better, with relatively few associated complications as compared to outdoor setting. Every institute should promulgate its own guidelines regarding hospitalization of such patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Bandyopadhyay A, Senapati S, Samanta DR, Mohanty S, Das PK (2015) Concurrent cisplatin-based chemotherapy versus radiotherapy alone as adjuvant therapy for squamous cell carcinoma of the oral cavity bearing high-risk features. Clin Cancer Invest J 4:610–616

    Article  CAS  Google Scholar 

  2. Wissinger E, Griebsch I, Lungershausen J, Foster T, Pashos CL (2014) The economic burden of head and neck cancer: a systematic literature review. Pharmacoeconomics 32(9):865–882

    Article  PubMed  PubMed Central  Google Scholar 

  3. Madani AH, Dikshit M, Bhaduri D (2012) Risk for oral cancer associated to smoking, smokeless and oral dip products. Indian J Public Health 56:57–60

    Article  PubMed  Google Scholar 

  4. Lango MN (2009) Multimodal treatment for head and neck cancer. Surg Clin N Am 89(1):43–52

    Article  PubMed  Google Scholar 

  5. Nair LM, Kumar RR, Thomachan KC, Rafi M, George PS et al (2017) Phase IIb trial comparing two concurrent cisplatin schedules in locally advancedhead and neck cancer. South Asian J Cancer 6(2):64–68

    PubMed  PubMed Central  Google Scholar 

  6. Givens DJ, Karnell LH, Gupta AK, Clamon GH, Pagedar NA et al (2009) Adverse events associated with concurrent chemoradiation therapy in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 135(12):1209–1217. doi:10.1001/archoto.2009.174

    Article  PubMed  Google Scholar 

  7. Mishra A, Meherotra R (2014) Head and neck cancer: global burden and regional trends in India. Asian Pac J Cancer Prev 15(2):537–550

    Article  PubMed  Google Scholar 

  8. National Cancer Institute. Common toxicity criteria (NCI-CTC) v4.0. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf

  9. Ghosh S, Rao PB, Kumar PR, Manam S (2015) Concurrent chemoradiation with weekly cisplatin for the treatment of head and neck cancers: an institutional study on acute toxicity and response to treatment. Asian Pac J Cancer Prev 16(16):7331–7335

    Article  PubMed  Google Scholar 

  10. Chaturvedi P (2009) Head and neck surgery. J Can Res Ther 5:143

    Article  Google Scholar 

  11. Kulkarni MR (2013) Head and neck cancer burden in India. Int J Head Neck Surg 4(1):29–35

    Article  Google Scholar 

  12. Adelstein DJ, Li Y, Adams GL et al (2003) An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21:92–98. doi:10.1200/JCO.2003.01.008

    Article  PubMed  Google Scholar 

  13. Al-Sarraf M, LeBlanc M, Giri PG et al (1998) Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. J Clin Oncol 16:1310–1317

    Article  CAS  PubMed  Google Scholar 

  14. Kanotra SP, Kanotra S, Gupta A, Paul J (2011) Chemoradiation in advanced head and neck cancers: a comparison of two radiosensitizers, paclitaxel and cisplatin. Indian J Otolaryngol Head Neck Surg 63(3):229–236

    Article  PubMed  PubMed Central  Google Scholar 

  15. Fan KY, Gogineni H, Zaboli D, Lake S, Zahurak ML et al (2012) Comparison of acute toxicities in two primary chemoradiation regimens in the treatment of advanced head and neck squamous cell carcinoma. Ann Surg Oncol 19(6):1980–1987. doi:10.1245/s10434-012-2219-4

    Article  PubMed  PubMed Central  Google Scholar 

  16. Epstein JB, Klasser GD (2006) Emerging approaches for prophylaxis and management of oropharyngeal mucositis in cancer therapy. Expert Opin Emerg Drugs 11(2):353–373

    Article  CAS  PubMed  Google Scholar 

  17. Bhide SA, Newbold KL, Harrington KJ, Nutting CM (1013) Clinical evaluation of intensity-modulated radiotherapy for head and neck cancers. Br J Radiol 2012(85):487–494

    Google Scholar 

  18. Ling DC, Kabolizadeh P, Heron DE, Ohr JP, Wang H et al (2015) Incidence of hospitalization in patients with head and neck cancer treated with intensity-modulated radiation therapy. Head Neck 37(12):1750–1755. doi:10.1002/hed.23821

    Article  PubMed  Google Scholar 

  19. Givens DJ, Karnell LH, Gupta AK, Clamon GH, Pagedar NA et al (2009) Adverse events associated with concurrent chemoradiation therapy in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 135(12):1209–1217. doi:10.1001/archoto.2009.174

    Article  PubMed  Google Scholar 

  20. Nguyen NP, Moltz CC, Frank C, Vos P, Smith HJ et al (2004) Dysphagia following chemoradiation for locally advanced head and neck cancer. Ann Oncol 15(3):383–388

    Article  CAS  PubMed  Google Scholar 

  21. Talwar B, Donnelly R, Skelly R, Donaldson M (2016) Nutritional management in head and neck cancer: United Kingdom national multidisciplinary guidelines. J Laryngol Otol 130(S2):S32–S40

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Zhang Z, Zhu Y, Ling Y, Zhang L, Wan H (2016) Comparative effects of different enteral feeding methods in head and neck cancer patients receiving radiotherapy or chemoradiotherapy: a network meta-analysis. Onco Targets Ther 9:2897–2909. doi:10.2147/OTT.S101983

    Article  PubMed  PubMed Central  Google Scholar 

  23. Shaw SM, Flowers H, O’Sullivan B, Hope A, Liu LW et al (2015) The effect of prophylactic percutaneous endoscopic gastrostomy (PEG) tube placement on swallowing and swallow-related outcomes in patients undergoing radiotherapy for head and neck cancer: a systematic review. Dysphagia 30(2):152–175. doi:10.1007/s00455-014-9592-z

    Article  PubMed  Google Scholar 

  24. Mekhail TM, Adelstein DJ, Rybicki LA, Larto MA, Saxton JP, Lavertu P (2001) Enteral nutrition during the treatment of head and neck carcinoma: is a percutaneous endoscopic gastrostomy tube preferable to a nasogastric tube? Cancer 91(9):1785–1790

    Article  CAS  PubMed  Google Scholar 

  25. Nguyen NP, Smith HJ, Dutta S, Alfieri A, North D et al (2007) Aspiration occurence during chemoradiation for head and neck cancer. Anticancer Res 27:1669–1672

    PubMed  Google Scholar 

  26. Xu B, Boero IJ, Hwang L, Le QT, Moiseenko V et al (2015) Aspiration pneumonia after concurrent chemoradiotherapy for head-and-neck cancer. Cancer 121(8):1303–1311

    Article  PubMed  Google Scholar 

  27. Lakshmaiah KC, Sirsath NT, Subramanyam JR, Babu K, Govind BK et al (2013) Aspiration in head and neck cancer patients: a single centre experience of clinical profile, bacterial isolates and antibiotic sensitivity pattern. Indian J Otolaryngol Head Neck Surg 65(1):144–149

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Madan R, Kairo AK, Sharma A, Roy S, Singh S et al (2015) Aspiration pneumonia related deaths in head and neck cancer patients: a retrospective analysis of risk factors from a tertiary care centre in North India. J Laryngol Otol 129(7):710–714. doi:10.1017/S0022215115001450

    Article  CAS  PubMed  Google Scholar 

  29. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI et al (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363(1):24–35. doi:10.1056/NEJMoa0912217

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Pignon JP, le Maître A, Bourhis J, MACH-NC Collaborative Group (2007) Meta-analyses of chemotherapy in head and neck cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys 69(2):S112–S114

    Article  PubMed  Google Scholar 

  31. Pignon JP, Baujat B, Bourhis J (2005) Individual patient data meta-analyses in head and neck carcinoma: what have we learnt? Cancer Radiother 9:31–36

    Article  PubMed  Google Scholar 

  32. Gupta PK, Lal P, Bajpai R, Goel A, Yadav R et al (2016) Long term results of comparison of concurrent low-dose daily cisplatin versus the standard weekly cisplatin with six fractions per week radiotherapy in locally advanced head neck cancer. South Asian J Cancer 5(2):80–84

    Article  PubMed  PubMed Central  Google Scholar 

  33. Kose F, Besen A, Sumbul T, Sezer A, Karadeniz C et al (2011) Weekly cisplatin versus standard three-weekly cisplatin in concurrent chemoradiotherapy of head and neck cancer: the Baskent University experience. Asian Pac J Cancer Prev 12(5):1185–1188

    PubMed  Google Scholar 

  34. Rawat S, Srivastava H, Ahlawat P, Pal M, Gupta G et al (2016) Weekly versus three-weekly cisplatin-based concurrent chemoradiotherapy as definitive treatment in head and neck cancer- where do we stand? Gulf J Oncol 1(21):6–11

    CAS  Google Scholar 

  35. Gupta T, Agarwal JP, Ghosh-Laskar S, Parikh PM, D’Cruz AK et al (2009) Radical radiotherapy with concurrent weekly cisplatin in loco-regionally advanced squamous cell carcinoma of the head and neck: a single-institution experience. Head Neck Oncol 15(1):17. doi:10.1186/1758-3284-1-17

    Article  CAS  Google Scholar 

  36. Dimri K, Pandey AK, Trehan R, Rai B, Kumar A (2013) Conventional radiotherapy with concurrent weekly cisplatin in locally advanced head and neck cancers of squamous cell origin—a single institution experience. Asian Pac J Cancer Prev 14(11):6883–6888

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors will like to thank Lt Col (Dr) Yadu Vir Singh MD (Community Medicine), PGD Epidemiology (PHFI) for his support in editing the manuscript and in providing statistical inputs.

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Army Hospital (R&R), Delhi Cantt, Delhi, 110010, India

    Virender Suhag, Pankaj Vats, N. Chakravarty, Tejas Pandya & Nishant Lohia

  2. Department of Pathology, Army Hospital (R&R), Delhi Cantt, Delhi, 110010, India

    B. S. Sunita

Authors
  1. Virender Suhag
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. S. Sunita
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pankaj Vats
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N. Chakravarty
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tejas Pandya
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nishant Lohia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B. S. Sunita.

Ethics declarations

Conflict of interest

There is no conflict of interest to declare.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

Informed Consent

All patients were treated by the standard of care as per international guidelines and written informed consent was taken from all participants.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Suhag, V., Sunita, B.S., Vats, P. et al. Tolerance of Chemoradiation in Advanced Head and Neck Cancers: Comparison Between Inpatients and Outpatients. Indian J Otolaryngol Head Neck Surg 71 (Suppl 1), 192–198 (2019). https://doi.org/10.1007/s12070-017-1210-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12070-017-1210-6

Keywords

Search

Navigation